VP, Investor Relations

Faeth Therapeutics•San Francisco, CA

10h•Remote

About The Position

Faeth Therapeutics is a clinical-stage oncology company listed on Nasdaq that recently raised $200M in funding. With a strong scientific foundation and a founding team that includes the discoverer of our target pathway, we are advancing PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor program, toward multiple near-term milestones. We are a small, focused team where every person has direct impact — united by a shared commitment to care deeply, create boldly, and never stop learning. The VP of Investor Relations will be the primary interface between the company and the investment community. This is a senior cross-functional role: you will work directly and frequently with the CEO, Chief Scientific Officer, Chief Medical Officer, and CFO to shape investor messaging, translate science into investment narrative, and ensure the company is consistently well-positioned with institutional investors and sell-side analysts. The ideal candidate brings institutional credibility, an ability to make complex oncology science legible to both specialist and generalist investors, and the organizational discipline to run a high-quality IR program at a lean, fast-moving company. You will own the IR function end-to-end — from investor targeting and conference scheduling to corporate narrative development and capital markets communications.

Requirements

8+ years of experience in investor relations, equity research, institutional sales, or a closely related field, with meaningful time spent in the biopharmaceutical or biotechnology sector.
Direct experience owning or managing an IR function at a public biotech or biopharma company, including ownership of conference and roadshow logistics.
Demonstrated ability to communicate complex science to both specialist and generalist investors in written and verbal formats.
Strong existing relationships with healthcare-focused institutional investors and/or sell-side analysts.
Deep understanding of Reg FD, SEC disclosure requirements, and public company IR best practices.
Exceptional organizational and project management skills; comfortable managing multiple priorities in a lean, remote-first environment.
Strong written and asynchronous communication skills appropriate for a distributed team.

Nice To Haves

Background in life science investor relations, with experience supporting clinical-stage companies through data readouts, trial initiations, or regulatory milestones.
Prior experience as a biotech buy-side analyst, sell-side analyst, or in equity capital markets at a life sciences-focused bank.
Familiarity with targeted oncology programs, or the competitive landscape in breast or endometrial cancer.
Experience supporting equity financing transactions, including PIPEs, follow-on offerings, or reverse mergers.
Undergraduate or graduate degree in life sciences, finance, or a related field.

Responsibilities

Build, manage, and continuously optimize a targeted investor outreach program — identifying high-fit institutional investors (long-only, crossover, and healthcare-focused hedge funds) and systematically tracking existing shareholders.
Manage all logistics for investor conferences, roadshows, non-deal roadshows, and one-on-one meetings — ensuring the leadership team is well-prepared, efficiently scheduled, and in front of the right audiences at the right moments.
Develop and maintain relationships with sell-side analysts and buy-side investors; serve as the day-to-day point of contact for inbound investor inquiries.
Proactively sequence the IR calendar around clinical milestones, data readouts, and corporate events so that investor communications are timely, coordinated, and impactful.
Partner closely with the CEO, CSO, CMO, and CFO to develop and continuously refine the company's investor narrative — including corporate presentation materials, FAQs, earnings scripts, the annual report, and key message frameworks.
Build and own the investment thesis for PIKTOR, including articulating the multi-node inhibition differentiation story, the competitive landscape, the CELC/gedatolisib read-through, and the company's near-term catalyst path across endometrial, breast, ovarian, and lung cancer indications.
Translate complex PI3K/AKT/mTOR biology and clinical data into clear, accurate, and compelling narratives appropriate for both specialist and generalist investors.
Ensure accuracy and consistency of all investor-facing materials in coordination with legal, regulatory, and compliance teams.
Lead preparation for quarterly earnings calls, including press releases, scripts, Q&A preparation, and post-call investor follow-up.
Manage the company's investor relations website and ensure timely, accurate disclosure of material information in compliance with Reg FD and SEC requirements.
Monitor and synthesize investor perception, consensus estimates, sell-side coverage, trading activity, and competitive intelligence; provide actionable reporting to senior leadership.
Coordinate with any retained external IR advisors and manage deliverables against the company's needs.
Serve as a trusted thought partner to the CFO on capital markets strategy — including timing, messaging, and investor targeting for any future financings or transactions.
Collaborate with clinical, regulatory, medical affairs, and legal teams to ensure investor communications around data readouts and regulatory milestones are accurate, appropriately framed, and strategically timed.
Support the board of directors with investor perception updates, competitive positioning, and market intelligence as needed.